» Articles » PMID: 39984655

Intratumour Oxidative Hotspots Provide a Niche for Cancer Cell Dissemination

Abstract

Intratumour heterogeneity represents the hierarchical integration of genetic, phenotypic and microenvironmental heterogeneity. Although single-cell sequencing has clarified genetic and phenotypic variability, the heterogeneity of nongenetic, microenvironmental factors remains elusive. Here, we developed T-AP1, a tumour-targeted probe tracking extracellular HO, which allows the visualization and characterization of tumour cells exposed to oxidative stress, a hallmark of cancer. T-AP1 identified actively budding intratumour regions as HO-rich microenvironments (HO hotspots), which were primarily established by neutrophils. Mechanistically, tumour cells exposed to HO underwent partial epithelial-mesenchymal transition through p38-MYC axis activation and migrated away from HO hotspots. This escape mechanism was absent in normal epithelial cells but prevalent in most cancers except NRF2-hyperactivated tumours, which exhibited abrogated p38 responses and enhanced antioxidant programmes, thus revealing an intrinsic stress defence programme in cancers. Together, T-AP1 enabled the identification of HO hotspots that provide a niche for cancer cell dissemination, offering insights into metastasis initiation.

References
1.
Tabassum D, Polyak K . Tumorigenesis: it takes a village. Nat Rev Cancer. 2015; 15(8):473-83. DOI: 10.1038/nrc3971. View

2.
Marusyk A, Janiszewska M, Polyak K . Intratumor Heterogeneity: The Rosetta Stone of Therapy Resistance. Cancer Cell. 2020; 37(4):471-484. PMC: 7181408. DOI: 10.1016/j.ccell.2020.03.007. View

3.
Baslan T, Hicks J . Unravelling biology and shifting paradigms in cancer with single-cell sequencing. Nat Rev Cancer. 2017; 17(9):557-569. DOI: 10.1038/nrc.2017.58. View

4.
Marine J, Dawson S, Dawson M . Non-genetic mechanisms of therapeutic resistance in cancer. Nat Rev Cancer. 2020; 20(12):743-756. DOI: 10.1038/s41568-020-00302-4. View

5.
Labrie M, Brugge J, Mills G, Zervantonakis I . Therapy resistance: opportunities created by adaptive responses to targeted therapies in cancer. Nat Rev Cancer. 2022; 22(6):323-339. PMC: 9149051. DOI: 10.1038/s41568-022-00454-5. View